FDA Rejects Avastin as Breast Cancer Drug; Genentech to Conduct New Trial to ID Best Responders | GenomeWeb

Originally published Nov. 18.

By Turna Ray

Genentech has failed to sway the US Food and Drug Administration to keep its oncologic Avastin on the market as a breast cancer treatment, but is planning a clinical trial that will evaluate whether a potential biomarker can determine best responders to the drug.

The FDA this week revoked Avastin's breast cancer indication "after concluding that the drug has not been shown to be safe and effective for that use."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.